false
Catalog
Self-Assessment: Novel Therapeutic Approaches for ...
Dr. Claytor Presentation
Dr. Claytor Presentation
Back to course
Pdf Summary
"Myasthenic Crisis – Diagnosis and Management" by Dr. Benjamin Claytor discusses myasthenic crisis (MC), a severe complication of myasthenia gravis (MG) characterized by respiratory failure requiring ventilatory support. The document covers epidemiology, risk factors, triggers, pathophysiology, diagnostic criteria, management strategies, outcomes, and prognosis.<br /><br />**Epidemiology and Risk Factors**: MC affects 2.5% of MG patients annually, often occurring within 8-12 months of MG diagnosis. Up to 30% of MC cases occur in patients without a prior MG diagnosis. Key risk factors include older age, previous MC episodes, oropharyngeal weakness, and thymoma.<br /><br />**Triggers**: Common triggers include infections (notably lung infections), reduced immunotherapy, surgery, trauma, medications, vaccination, pregnancy, and unknown factors (~20-40%).<br /><br />**Pathophysiology**: MC develops over days and involves weakness of respiratory muscles and oropharyngeal muscles, leading to respiratory failure and potential aspiration.<br /><br />**Diagnosis and Differential Diagnosis**: Diagnosing MC involves confirming the diagnosis of MG (if not previously diagnosed), excluding other causes of respiratory failure, and monitoring specific clinical signs like neck flexion weakness and difficulty with phonation. Differential diagnoses include Guillain-Barre syndrome and motor neuron disease, among others.<br /><br />**Management in ICU**: The management focuses on respiratory support via intubation or BiPAP, treating infections, and preventing complications with supportive care. Immune treatments include IVIG, plasma exchange, and corticosteroids. Criteria for extubation and post-extubation care are detailed to reduce the risk of re-intubation.<br /><br />**Prognosis and Complications**: The prognosis of MC patients has improved, but complications such as deep vein thrombosis and cardiac events can occur. Functional dependence is common after prolonged intubation.<br /><br />**Newer Therapies and Medications**: Innovations like Eculizumab and Rituximab show promise for patients unresponsive to traditional treatments. Medications used in ICU require caution to prevent exacerbation of MG symptoms.<br /><br />**Psychocognitive and Caregiver Impact**: ICU admission can lead to cognitive impairment, anxiety, depression, and PTSD for both patients and caregivers.<br /><br />The document underscores the importance of timely and comprehensive care and follow-up for individuals experiencing a myasthenic crisis.
Keywords
Myasthenic Crisis
Myasthenia Gravis
Respiratory Failure
Epidemiology
Risk Factors
Triggers
Pathophysiology
Diagnosis
Management
Prognosis
2621 Superior Drive NW
Rochester, MN
P
507.288.0100
F
507.288.1225
aanem@aanem.org
Terms of Use
Privacy Statement
© 2024 American Association of Neuromuscular & Electrodiagnostic Medicine
×
Please select your language
1
English